Terms ending in 2040
Every in-force patent on Cybin UK Ltd.'s record whose computed term ends in 2040, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,771,681 | Therapeutic Compounds In force · Medium confidence | Cybin UK Ltd. | In force | Medium confidence | |
| US 12,076,311 | Therapeutic Compositions Comprising Deuterated or Partially Deuterated N,n-Dimethyltryptamine Compounds In force · Medium confidence | Cybin UK Ltd. | In force | Medium confidence | |
| US 11,406,619 | Injectable Formulations In force · High confidence | Cybin UK Ltd. | In force | High confidence | |
| US 12,343,327 | Injectable Formulations In force · High confidence | Cybin UK Ltd. | In force | High confidence | |
| US 11,578,039 | Compounds In force · Medium confidence | Cybin UK Ltd. | In force | Medium confidence | |
| US 11,643,390 | Synthesis of N,n-Dimethyltryptamine-Type Compounds, Methods, and Uses In force · High confidence | Cybin UK Ltd. | In force | High confidence | |
| US 12,084,417 | Synthesis of N,n-Dimethyltryptamine-Type Compounds, Methods, and Uses In force · High confidence | Cybin UK Ltd. | In force | High confidence | |
| US 12,157,723 | Compounds In force · Medium confidence | Cybin UK Ltd. | In force | Medium confidence | |
| US 12,649,718 | Synthesis of N,n-Dimethyltryptamine-Type Compounds, Methods, and Uses In force · Medium confidence | Cybin UK Ltd. | In force | Medium confidence |
9 of 9 patents shown. Soonest term end first, then patent number.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.